LAB at a glance
STANDARD BIOTOOLS INC. (LAB, SEC CIK 1162194) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on October 5, 2026 and Form 4 insider filings as recently as August 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), STANDARD BIOTOOLS INC. (LAB) reported revenue of $85.3 million (down 51.1% from FY2024) and a net loss of $74.9 million. Diluted EPS was -$0.20.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding STANDARD BIOTOOLS INC. (LAB) shares worth $81.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $85.3M
- −51.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $81.1M · +0 vs prior quarter
- Latest 8-K
- Sep 30, 2026
- Item 1.01 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $20.1M, down 8% YoY from $21.8M, driven by consumables down 10% to $9.4M
- Gross margin 52.4% vs 48.8% YoY; net loss $26.8M vs $33.5M
- Best performer consumables at $9.4M; instruments declined 2% to $5.1M
- Cash, equivalents and investments $544.0M vs $213.3M at December 31, 2025
- Six-month operating cash use $56.9M vs $51.0M; merger expected to close second half of 2026
Risk Factors
- Nasdaq compliance risk: $1.00 bid-price deficiency recurred July 22, 2026, with compliance deadline January 19, 2027
- Merger execution risk: Closing remains subject to stockholder, Nasdaq listing, Form S-4 effectiveness, and other conditions
- Merger termination exposure: $16.1 million cash fee plus up to $5 million expense reimbursement
- Strategic transition risk: Combined company expected to shift from instruments to clinical-stage biopharmaceuticals
- Ownership dilution risk: Treeline holders expected to own 84% versus current stockholders’ 16% post-merger
AI summary of the LAB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Multiplex Bio Purchase Agreement governs the previously disclosed transaction
- Terms incorporated by reference from July 28, 2026 Form 8-K, amended July 29, 2026
Item EX-99.1: Item EX-99.1
- Multiplex Bio sale terminated; Mass Cytometry business sold to GMT Venture’s Element Biosystems for $5.5 million cash
- Avoiding Multiplex’s required $10 million working-capital loan improves Treeline merger exchange-ratio net cash by approximately $15 million
Item 7.01: Regulation FD Disclosure
- Reg FD disclosure concerns proposed Business disposition and Merger involving Treeline, GMT Venture and Element
- Transactions remain subject to stockholder approvals, closing conditions and potential competing proposals
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 filing contains only the signature block, not operating results or financial metrics
- CFO Alex Kim signed the report for Standard BioTools on August 5, 2026
Item 7.01: Regulation FD Disclosure
- Regulation FD disclosure incorporates the “Full Year 2026 Revenue Outlook” into the filing
- Revenue outlook details appear in the referenced exhibit, alongside company background and forward-looking-risk language
Item EX-99.1: Item EX-99.1
- Q2 revenue $20.1M, down 7.6% YoY amid weaker consumables, instruments, and services demand
- Adjusted EBITDA loss improved 84% to $2.5M, supported by 50% lower non-GAAP operating expenses
AI summaries of LAB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LAB
Don't miss the next LAB filing
- Alerts as it files. A push when LAB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LAB, by share count.
- Ask anything. An AI agent that reads every LAB filing and answers with sources.
LAB alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kim Hanjoon Alex | F | Aug 20, 2026 | 28,195 | $0.67 |
| Egholm Michael | F | Aug 20, 2026 | 97,627 | $0.67 |
| Mackay Sean | F | Aug 20, 2026 | 25,729 | $0.67 |
| Egholm Michael | F | Aug 3, 2026 | 362,625 | $0.87 |
| Kim Hanjoon Alex | F | Jul 23, 2026 | 202,476 | $0.90 |
| Mackay Sean | A | Jun 20, 2026 | 500,000 | - |
| Cox Troy | A | Jun 18, 2026 | 175,923 | - |
| Cox Troy | A | Jun 18, 2026 | 99,116 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $174.4M | $85.3M |
| Gross Profit | - | $84.3M | $42.5M |
| Operating Income | - | -$175.2M | -$110.2M |
| Net Income | - | -$138.9M | -$74.9M |
| Gross Margin | - | 48.3% | 49.9% |
| Op. Margin | - | -100.5% | -129.2% |
| Net Margin | - | -79.6% | -87.8% |
| Balance Sheet | |||
| Total Assets | $323.1M | $612.3M | $567.8M |
| Equity | - | $471.7M | $424.3M |
| ROE | - | -29.4% | -17.7% |
| Per Share | |||
| EPS | - | $-0.52 | $-0.20 |
| Cash Flow | |||
| Operating CF | - | -$143.5M | -$74.3M |
| CapEx | $2.8M | $8.4M | $8.3M |
Source: XBRL data in STANDARD BIOTOOLS INC. (LAB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate LAB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $81.1M |
| Q1 2026 | 28 | $108.7M |
| Q4 2025 | 26 | $165.5M |
| Q3 2025 | 25 | $162.7M |
| Q2 2025 | 26 | $150.8M |
| Q1 2025 | 21 | $115.9M |
| Q4 2024 | 18 | $170.7M |
| Q3 2024 | 18 | $164.4M |
- D.E. Shaw & Co+2.62M (+1315%)
- Millennium Management+1.41M (+67%)
- Citadel Advisors LLC+1.12M (+92%)
- AQR Capital Management+425.9K (+46%)
- Prudential Financial+12.9K (+27%)
- BlackRock−16.50M (-67%)
- State Street Corp−5.01M (-76%)
- Vanguard Portfolio Management LLC−1.72M (-72%)
- Northern Trust−1.66M (-68%)
- Goldman Sachs Group−726.8K (-77%)
- Loews Corporation+1.25M
- Renaissance Technologies LLC+992.1K
- Ameriprise Financial+104.8K
- T. Rowe Price Group−202.5K
- M&T Bank−23.6K
- Principal Financial Group−13.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 190 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LAB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 5, 2026 | - | - | - |
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 4 | Jul 27, 2026 | - | - | - |
| 8-K | Jul 24, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| SC 13D | Jun 12, 2026 | - | - | |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 8-K | Jun 3, 2026 | - | Analysis |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
LAB SEC filings: frequently asked questions
Which institutions hold LAB stock?
As of June 30, 2026, the largest STANDARD BIOTOOLS INC. (LAB) holders among the 13F filers tracked by SignalX were Viking Global Investors ($48.3 million), Vanguard Capital Management LLC ($10.1 million), BlackRock ($6.8 million), Millennium Management ($2.9 million), Morgan Stanley ($2.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LAB's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), STANDARD BIOTOOLS INC. (LAB) reported revenue of $85.3 million (down 51.1% from FY2024) and a net loss of $74.9 million. Diluted EPS was -$0.20. The figures come from the XBRL data in the 10-K.
What did LAB report in its latest 8-K?
STANDARD BIOTOOLS INC. (LAB) filed an 8-K on September 30, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 7.01 (Regulation FD Disclosure). Multiplex Bio Purchase Agreement governs the previously disclosed transaction.
What are the latest LAB SEC filings?
STANDARD BIOTOOLS INC. (LAB) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on October 5, 2026 and a Form 4 insider filing on August 24, 2026.
What is LAB's SEC CIK number?
STANDARD BIOTOOLS INC. (LAB)'s SEC Central Index Key (CIK) is 1162194. EDGAR lists every LAB filing under that number.
Ask anything about LAB
The research agent reads LAB's filings, financials, insider trades and 13F holders, then answers with sources.